NASDAQ$CBUS

Cibus Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Evolved strategic direction to focus innovations on plant-based technology and production.

Calyxt reported a decrease in revenue due to the wind-down of its soybean product line, but net loss improved due to improved gross profits and reduced operating expenses. The company achieved milestones in operationalizing its BioFactory production system and expanded its AIML capabilities.

  • Operationalized the initial pilot BioFactory production system.
  • Expanded AIML capabilities across the PlantSpring technology platform.
  • Advanced discussions with potential customers in cosmeceutical, nutraceutical, and pharmaceutical industries.
  • Closed SEC-registered offering of common stock generating gross proceeds of $10.9 million.

Headline financials

Total Revenue

$1.94M

Previous: $13.9M-86.0%
EPS (adj)

-$0.90

Previous: -$6.60+86.4%
Capital Expenditures

$121K

Previous: $640K-81.1%
Free Cash Flow

-$33.6M

Previous: -$13.3M-152.3%
Net Income

-$7.06M

Previous: -$13.4M+47.3%
Operating Income

-$6.71M

Previous: -$13M+48.3%
Gross Profit

-$61K

Previous: -$4.94M+98.8%
Cash & Equivalents

$13.8M

Previous: $17.3M-20.1%
Total Assets

$37.2M

Previous: $63.3M-41.3%
Stock-Based Comp

$1.23M

Previous: $1.33M-8.1%

Revenue & EPS history

Cibus · Revenue · Quarterly

$1.94M

Q4 2021-86%vs Q4 2020
Beat estimate in 0 of 2 quarters(0%)
ActualEstimate

Forward guidance

Calyxt anticipates that the proceeds from the offering will be used to support the continued growth and scaling of its BioFactory business model and selective hiring to support the progression and expansion of its AIML capabilities. Calyxt expects its cash runway to extend to late 2022.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-1.1%

Avg return

Earnings day

-2.2%

Avg return

5 days after

-12.4%

Avg return

30 days after

37%

13 / 35 earnings

Positive

+23.6%

Q4 2019

Best reaction

-25.1%

Q4 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.8%-10.3%
Q4 2025-16.7%-24.7%-56.8%
Q3 2025-0.8%+1.6%+28.8%
Q2 2025-3.5%-11.6%-7.5%
Q1 2025-7.8%-8.1%-29.4%
Q4 2024-6.4%-9.6%-23.7%
Q3 2024+14.5%+15.2%-8.9%
Q2 2024-9.2%+2.7%-42.4%
Q1 2024+2.2%+9.5%-37.5%
Q4 2023-0.7%+2.2%+7.4%
Q3 2023+17.0%+5.0%-8.8%
Q2 2023-9.7%-13.8%-19.8%
Q1 2023-3.6%-8.3%-15.8%
Q4 2022+1.6%-0.7%-21.5%
Q3 2022-1.4%-7.7%+22.5%
Q2 2022+12.4%+4.3%-11.6%
Q1 2022-17.3%-27.4%-60.0%
Q4 2021-2.8%-21.3%-20.6%
Q3 2021-7.4%-9.0%-41.9%
Q2 2021+12.0%+15.1%+19.9%
Q1 2021+4.6%+3.3%-17.4%
Q4 2020-25.1%-24.7%-35.6%
Q3 2020-1.4%-4.0%-44.3%
Q2 2020-6.6%+0.2%-8.3%
Q1 2020-15.0%-9.4%+27.9%
Q4 2019+23.6%+22.7%-10.1%
Q3 2019-9.7%-10.2%-16.3%
Q2 2019+2.7%-13.1%-23.9%
Q1 2019-3.5%-6.7%-9.3%
Q4 2018+8.3%+20.0%+34.0%
Q3 2018-2.9%-4.9%-22.1%
Q2 2018-0.7%-3.1%-10.8%
Q1 2018+1.9%+22.1%+28.1%
Q4 2017+6.4%+18.8%+16.9%
Q3 2017+7.8%+8.2%-2.2%
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro